Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani; Julia M. Akeroyd; Vijay Nambi; Erin D. Michos; Pamela B. Morris; Khurram Nasir; Sidney C. Smith; Neil J. Stone; Laura A. Petersen; Christie M. Ballantyne

doi:10.1161/CIRCULATIONAHA.118.034993

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani^*, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	410-412
Number of pages	3
Journal	Circulation
Volume	139
Issue number	3
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.118.034993
State	Published - Jan 15 2019

Funding

This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.

Keywords

cholesterol
clinical trial

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.118.034993

Cite this

Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A., & Ballantyne, C. M. (2019). Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs. Circulation, 139(3), 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

@article{ece5249b61f646eb8b722bdbf701883a,

title = "Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs",

keywords = "cholesterol, clinical trial",

author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Vijay Nambi and Michos, {Erin D.} and Morris, {Pamela B.} and Khurram Nasir and Smith, {Sidney C.} and Stone, {Neil J.} and Petersen, {Laura A.} and Ballantyne, {Christie M.}",

note = "Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.",

year = "2019",

month = jan,

day = "15",

doi = "10.1161/CIRCULATIONAHA.118.034993",

language = "English (US)",

volume = "139",

pages = "410--412",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

Virani, SS, Akeroyd, JM, Nambi, V, Michos, ED, Morris, PB, Nasir, K, Smith, SC, Stone, NJ, Petersen, LA & Ballantyne, CM 2019, 'Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs', Circulation, vol. 139, no. 3, pp. 410-412. https://doi.org/10.1161/CIRCULATIONAHA.118.034993

TY - JOUR

T1 - Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial

T2 - Insights From the Department of Veterans Affairs

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Michos, Erin D.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Smith, Sidney C.

AU - Stone, Neil J.

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

N1 - Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.

PY - 2019/1/15

Y1 - 2019/1/15

KW - cholesterol

KW - clinical trial

UR - http://www.scopus.com/inward/record.url?scp=85060035929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060035929&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.118.034993

DO - 10.1161/CIRCULATIONAHA.118.034993

M3 - Letter

C2 - 30586689

AN - SCOPUS:85060035929

SN - 0009-7322

VL - 139

SP - 410

EP - 412

JO - Circulation

JF - Circulation

IS - 3

ER -

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this